100 related articles for article (PubMed ID: 7785879)
1. Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase.
Maksimenko AV; Petrov AD; Tischenko EG; Smirnov MD
Ann N Y Acad Sci; 1995 Mar; 750():496-501. PubMed ID: 7785879
[No Abstract] [Full Text] [Related]
2. [Development of the high effective thrombolytic agents with molecular biological technique].
Wu HZ; Li JZ
Zhonghua Nei Ke Za Zhi; 1993 Jan; 32(1):11-3. PubMed ID: 8404311
[No Abstract] [Full Text] [Related]
3. Amediplase. Menarini.
Doggrell SA
Curr Opin Investig Drugs; 2004 Mar; 5(3):344-7. PubMed ID: 15083603
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic agents.
Collen D; Lijnen HR
Thromb Haemost; 2005 Apr; 93(4):627-30. PubMed ID: 15841305
[TBL] [Abstract][Full Text] [Related]
5. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
6. [Inactivation and stabilization of urokinase fibrinolytic activity in vitro].
Aĭsina RB; Mukhametova LI; Sazonova IIu; Varfolomeev SD
Bioorg Khim; 1998 Jul; 24(7):544-8. PubMed ID: 9749317
[TBL] [Abstract][Full Text] [Related]
7. The ideal fibrinolytic: can drug design improve clinical results?
Van de Werf FJ
Eur Heart J; 1999 Oct; 20(20):1452-8. PubMed ID: 10493843
[No Abstract] [Full Text] [Related]
8. [Coronary thrombolytic agents and their characteristics].
Yoshinaga M; Kambara H
Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):775-81. PubMed ID: 12436615
[No Abstract] [Full Text] [Related]
9. Co-immobilization of urokinase and thrombomodulin on islet surfaces by poly(ethylene glycol)-conjugated phospholipid.
Chen H; Teramura Y; Iwata H
J Control Release; 2011 Mar; 150(2):229-34. PubMed ID: 21108976
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical, pharmacologic and clinical properties of new thrombolytic agents].
Gulba DC
Internist (Berl); 1996 Jun; 37(6):552-66. PubMed ID: 8767988
[No Abstract] [Full Text] [Related]
11. Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
Goto S; Handa S; Kawai Y; Watanabe K; Abe S; Takahashi E; Hori S; Ikeda Y
Cardiology; 1992; 80(3-4):252-6. PubMed ID: 1387346
[TBL] [Abstract][Full Text] [Related]
12. Thrombolytic agents in development.
Verstraete M; Lijnen HR; Collen D
Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
[TBL] [Abstract][Full Text] [Related]
13. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
14. Urokinase activity after freezing: implications for thrombolysis in intraventricular hemorrhage.
Rhoney DH; Coplin WM; Zaran FK; Brish LK; Weingarten CM
Am J Health Syst Pharm; 1999 Oct; 56(20):2047-51. PubMed ID: 10541031
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic agents.
Gurewich V
N Engl J Med; 1994 Jan; 330(4):291. PubMed ID: 8272100
[No Abstract] [Full Text] [Related]
17. [Thrombolytic action of urokinase preparation covalently bound to modified thrombin].
Maksimenko AV; Tishvhenko EG; Petrov AD; Orekhova NM; Ragimov SE
Biull Eksp Biol Med; 1988 Sep; 106(9):322-4. PubMed ID: 3167185
[TBL] [Abstract][Full Text] [Related]
18. Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors.
Tsuda Y; Tada M; Wanaka K; Okamoto U; Hijikata-Okunomiya A; Okamoto S; Okad Y
Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1457-63. PubMed ID: 11724238
[TBL] [Abstract][Full Text] [Related]
19. Effective enzyme thrombolytic composition on the basis of wild-type and chemically modified plasminogen activators.
Maksimenko AV; Tischenko EG; Petrov AD; Petrova ML
Ann N Y Acad Sci; 1996 Oct; 799():146-50. PubMed ID: 8958085
[No Abstract] [Full Text] [Related]
20. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
Husain SS
Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
